Opis działalności
Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with brain disease. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at diseases such as depression and anxiety, psychotic disorders, epilepsy and Huntington’s, Alzheimer’s and Parkinson’s diseases.
Zarząd & Rada nadzorcza
| CEO |
| Dr. Deborah Dunsire |
| Zarząd |
| Anders Götzsche, Dr. Johan Luthman, Elise Hauge, Jacob Tolstrup, Keld Flintholm Jørgensen, Lars Bang |
| Rada nadzorcza |
| Lars Rasmussen, Dorothea Wenzel, Henrik Sindal Jensen, Jeffrey Berkowitz, Jeremy M. Levin, Lars Holmqvist, Lene Skole-Sørensen, Ludovic Tranholm Otterbein, Rikke Kruse Andreasen, Santiago Arroyo |
Dane firmy
| Nazwa: |
H. Lundbeck A/S |
| Adres: |
Ottiliavej 9,DK-2500 Valby |
| Telefon: |
+45-3630-1311 |
| Fax: |
+45-3630-1940 |
| E-mail: |
information@lundbeck.com
|
| Internet: |
www.lundbeck.com/ |
| Przemysł: |
Służba zdrowia |
| Sektor: |
Przemysł Farmaceutyczny |
| Podsektor: |
Przemysł Farmaceutyczny |
| Koniec roku finansowego: |
31.12 |
| Free float: |
31,00% |
| Data IPO: |
- |
Relacje inwestorskie
| Nazwa: |
Palle Holm Olesen |
| Telefon: |
+45-3643-2426 |
| Fax: |
- |
| E-mail: |
investor@lundbeck.com
|
